Willow Shah-Neville

Find out how the recent discovery of a bacterial molecular oddity known as bridge RNA, has led to the creation of a novel gene editing tool.

Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.

The biotech industry thrives on partnerships, as they help to drive innovation through the sharing of knowledge, expertise, and resources.

The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.

Circular RNA is an emerging technology that experts believe holds a lot of promise for next-generation vaccines and gene therapies.

Antisense oligonucleotides, which target the disease source at the RNA level, have gained a lot of popularity in recent years among drug developers.

Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market.

The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024.

Discover all you need to know about stealth mode biotech startups, including what stealth mode is and its advantages and disadvantages.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like.